ES2365626T7 - Método de detección o seguimiento de una enfermedad maligna de las células plasmáticas - Google Patents
Método de detección o seguimiento de una enfermedad maligna de las células plasmáticas Download PDFInfo
- Publication number
- ES2365626T7 ES2365626T7 ES06703629.3T ES06703629T ES2365626T7 ES 2365626 T7 ES2365626 T7 ES 2365626T7 ES 06703629 T ES06703629 T ES 06703629T ES 2365626 T7 ES2365626 T7 ES 2365626T7
- Authority
- ES
- Spain
- Prior art keywords
- antibodies
- iga
- antibody
- heavy chain
- fragments
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000000034 method Methods 0.000 title claims abstract description 68
- 230000003211 malignant effect Effects 0.000 title claims abstract description 17
- 238000012544 monitoring process Methods 0.000 title claims abstract description 16
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims description 50
- 201000010099 disease Diseases 0.000 title claims description 48
- 210000004180 plasmocyte Anatomy 0.000 title claims description 25
- 108060003951 Immunoglobulin Proteins 0.000 claims abstract description 89
- 102000018358 immunoglobulin Human genes 0.000 claims abstract description 89
- 229940072221 immunoglobulins Drugs 0.000 claims abstract description 53
- 238000003556 assay Methods 0.000 claims abstract description 38
- 230000027455 binding Effects 0.000 claims abstract description 25
- 239000011324 bead Substances 0.000 claims abstract description 17
- 239000000758 substrate Substances 0.000 claims abstract description 14
- 239000012634 fragment Substances 0.000 claims description 51
- 210000002966 serum Anatomy 0.000 claims description 35
- 238000012360 testing method Methods 0.000 claims description 29
- 238000012286 ELISA Assay Methods 0.000 claims description 18
- 238000001514 detection method Methods 0.000 claims description 15
- 238000000684 flow cytometry Methods 0.000 claims description 13
- 210000004369 blood Anatomy 0.000 claims description 10
- 239000008280 blood Substances 0.000 claims description 10
- 102000004190 Enzymes Human genes 0.000 claims description 8
- 108090000790 Enzymes Proteins 0.000 claims description 8
- 210000002700 urine Anatomy 0.000 claims description 8
- 229920000126 latex Polymers 0.000 claims description 6
- 239000004816 latex Substances 0.000 claims description 6
- 102000013463 Immunoglobulin Light Chains Human genes 0.000 claims description 5
- 108010065825 Immunoglobulin Light Chains Proteins 0.000 claims description 5
- 239000004793 Polystyrene Substances 0.000 claims description 5
- 229920002223 polystyrene Polymers 0.000 claims description 5
- 238000002493 microarray Methods 0.000 claims description 4
- 239000000203 mixture Substances 0.000 claims description 4
- 238000003149 assay kit Methods 0.000 claims 1
- 238000005406 washing Methods 0.000 abstract description 3
- 208000021161 Plasma cell disease Diseases 0.000 abstract description 2
- 239000000523 sample Substances 0.000 description 34
- 206010035226 Plasma cell myeloma Diseases 0.000 description 33
- 208000034578 Multiple myelomas Diseases 0.000 description 18
- 241001494479 Pecora Species 0.000 description 16
- 238000001962 electrophoresis Methods 0.000 description 16
- 201000000050 myeloid neoplasm Diseases 0.000 description 14
- 102000004169 proteins and genes Human genes 0.000 description 14
- 108090000623 proteins and genes Proteins 0.000 description 14
- 238000010790 dilution Methods 0.000 description 10
- 239000012895 dilution Substances 0.000 description 10
- 102000004506 Blood Proteins Human genes 0.000 description 9
- 108010017384 Blood Proteins Proteins 0.000 description 9
- 230000002159 abnormal effect Effects 0.000 description 9
- 238000004519 manufacturing process Methods 0.000 description 9
- 238000004848 nephelometry Methods 0.000 description 9
- 230000035945 sensitivity Effects 0.000 description 9
- 238000011088 calibration curve Methods 0.000 description 7
- 238000005259 measurement Methods 0.000 description 7
- 201000005328 monoclonal gammopathy of uncertain significance Diseases 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 206010020631 Hypergammaglobulinaemia benign monoclonal Diseases 0.000 description 6
- 206010028980 Neoplasm Diseases 0.000 description 6
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 6
- 208000007452 Plasmacytoma Diseases 0.000 description 6
- 239000011049 pearl Substances 0.000 description 6
- 208000005531 Immunoglobulin Light-chain Amyloidosis Diseases 0.000 description 5
- 208000033559 Waldenström macroglobulinemia Diseases 0.000 description 5
- 239000000427 antigen Substances 0.000 description 5
- 108091007433 antigens Proteins 0.000 description 5
- 102000036639 antigens Human genes 0.000 description 5
- 238000003745 diagnosis Methods 0.000 description 5
- 239000003085 diluting agent Substances 0.000 description 5
- 238000002372 labelling Methods 0.000 description 5
- 208000023761 AL amyloidosis Diseases 0.000 description 4
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 4
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 4
- 208000002774 Paraproteinemias Diseases 0.000 description 4
- 238000002835 absorbance Methods 0.000 description 4
- 210000003719 b-lymphocyte Anatomy 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 238000000760 immunoelectrophoresis Methods 0.000 description 4
- 208000015270 non-secretory plasma cell myeloma Diseases 0.000 description 4
- 230000009870 specific binding Effects 0.000 description 4
- 239000011534 wash buffer Substances 0.000 description 4
- UAIUNKRWKOVEES-UHFFFAOYSA-N 3,3',5,5'-tetramethylbenzidine Chemical compound CC1=C(N)C(C)=CC(C=2C=C(C)C(N)=C(C)C=2)=C1 UAIUNKRWKOVEES-UHFFFAOYSA-N 0.000 description 3
- NHZLNPMOSADWGC-UHFFFAOYSA-N 4-amino-N-(2-quinoxalinyl)benzenesulfonamide Chemical compound C1=CC(N)=CC=C1S(=O)(=O)NC1=CN=C(C=CC=C2)C2=N1 NHZLNPMOSADWGC-UHFFFAOYSA-N 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 238000000149 argon plasma sintering Methods 0.000 description 3
- 210000001185 bone marrow Anatomy 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 238000003018 immunoassay Methods 0.000 description 3
- 229940127121 immunoconjugate Drugs 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 230000002335 preservative effect Effects 0.000 description 3
- 238000011002 quantification Methods 0.000 description 3
- 239000003381 stabilizer Substances 0.000 description 3
- 238000004879 turbidimetry Methods 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 2
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 2
- 208000028564 B-cell non-Hodgkin lymphoma Diseases 0.000 description 2
- -1 BODIPY Chemical compound 0.000 description 2
- 208000002250 Hematologic Neoplasms Diseases 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 2
- 208000010159 IgA glomerulonephritis Diseases 0.000 description 2
- 206010021263 IgA nephropathy Diseases 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 206010060880 Monoclonal gammopathy Diseases 0.000 description 2
- 229920001213 Polysorbate 20 Polymers 0.000 description 2
- 208000001647 Renal Insufficiency Diseases 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 239000012491 analyte Substances 0.000 description 2
- 239000002981 blocking agent Substances 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 238000005515 capillary zone electrophoresis Methods 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 231100000517 death Toxicity 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 201000006569 extramedullary plasmacytoma Diseases 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 2
- 239000010931 gold Substances 0.000 description 2
- 229910052737 gold Inorganic materials 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 230000003053 immunization Effects 0.000 description 2
- 238000002649 immunization Methods 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 201000006370 kidney failure Diseases 0.000 description 2
- 238000001462 microwave scanning near-field microscopy Methods 0.000 description 2
- 239000000178 monomer Substances 0.000 description 2
- JPMIIZHYYWMHDT-UHFFFAOYSA-N octhilinone Chemical compound CCCCCCCCN1SC=CC1=O JPMIIZHYYWMHDT-UHFFFAOYSA-N 0.000 description 2
- 239000002953 phosphate buffered saline Substances 0.000 description 2
- 239000000049 pigment Substances 0.000 description 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
- 230000001376 precipitating effect Effects 0.000 description 2
- 208000022256 primary systemic amyloidosis Diseases 0.000 description 2
- 230000002062 proliferating effect Effects 0.000 description 2
- 238000000159 protein binding assay Methods 0.000 description 2
- 230000002285 radioactive effect Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 238000013207 serial dilution Methods 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- VGIRNWJSIRVFRT-UHFFFAOYSA-N 2',7'-difluorofluorescein Chemical compound OC(=O)C1=CC=CC=C1C1=C2C=C(F)C(=O)C=C2OC2=CC(O)=C(F)C=C21 VGIRNWJSIRVFRT-UHFFFAOYSA-N 0.000 description 1
- 208000035285 Allergic Seasonal Rhinitis Diseases 0.000 description 1
- 208000037259 Amyloid Plaque Diseases 0.000 description 1
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 1
- 206010061728 Bone lesion Diseases 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 208000037147 Hypercalcaemia Diseases 0.000 description 1
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 description 1
- 208000028018 Lymphocytic leukaemia Diseases 0.000 description 1
- 208000030289 Lymphoproliferative disease Diseases 0.000 description 1
- 208000010190 Monoclonal Gammopathy of Undetermined Significance Diseases 0.000 description 1
- 206010058116 Nephrogenic anaemia Diseases 0.000 description 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 210000000628 antibody-producing cell Anatomy 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 210000003651 basophil Anatomy 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 239000003139 biocide Substances 0.000 description 1
- 239000013060 biological fluid Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- CZPLANDPABRVHX-UHFFFAOYSA-N cascade blue Chemical compound C=1C2=CC=CC=C2C(NCC)=CC=1C(C=1C=CC(=CC=1)N(CC)CC)=C1C=CC(=[N+](CC)CC)C=C1 CZPLANDPABRVHX-UHFFFAOYSA-N 0.000 description 1
- PTIUZRZHZRYCJE-UHFFFAOYSA-N cascade yellow Chemical compound C1=C(S([O-])(=O)=O)C(OC)=CC=C1C1=CN=C(C=2C=C[N+](CC=3C=C(C=CC=3)C(=O)ON3C(CCC3=O)=O)=CC=2)O1 PTIUZRZHZRYCJE-UHFFFAOYSA-N 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 description 1
- 238000005352 clarification Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 238000004737 colorimetric analysis Methods 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 239000002274 desiccant Substances 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 201000005787 hematologic cancer Diseases 0.000 description 1
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 description 1
- 210000003630 histaminocyte Anatomy 0.000 description 1
- 230000000148 hypercalcaemia Effects 0.000 description 1
- 208000030915 hypercalcemia disease Diseases 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 208000003747 lymphoid leukemia Diseases 0.000 description 1
- 201000001268 lymphoproliferative syndrome Diseases 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 238000007837 multiplex assay Methods 0.000 description 1
- 108010002125 myeloma immunoglobulins Proteins 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- VYNDHICBIRRPFP-UHFFFAOYSA-N pacific blue Chemical compound FC1=C(O)C(F)=C2OC(=O)C(C(=O)O)=CC2=C1 VYNDHICBIRRPFP-UHFFFAOYSA-N 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 239000013610 patient sample Substances 0.000 description 1
- 210000000578 peripheral nerve Anatomy 0.000 description 1
- 102000013415 peroxidase activity proteins Human genes 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 208000031223 plasma cell leukemia Diseases 0.000 description 1
- 238000002616 plasmapheresis Methods 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6854—Immunoglobulins
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57426—Specifically defined cancers leukemia
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Pathology (AREA)
- Microbiology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Peptides Or Proteins (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0501741 | 2005-01-27 | ||
| GBGB0501741.3A GB0501741D0 (en) | 2005-01-27 | 2005-01-27 | Antibody |
| PCT/GB2006/000267 WO2006079816A1 (en) | 2005-01-27 | 2006-01-26 | Method of detecting or monitoring a malignant plasma cell disease |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| ES2365626T3 ES2365626T3 (es) | 2011-10-07 |
| ES2365626T7 true ES2365626T7 (es) | 2014-06-04 |
Family
ID=34259791
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES06703629.3T Active ES2365626T7 (es) | 2005-01-27 | 2006-01-26 | Método de detección o seguimiento de una enfermedad maligna de las células plasmáticas |
| ES10196249.6T Active ES2455440T3 (es) | 2005-01-27 | 2006-01-26 | Método de detección o seguimiento de una enfermedad maligna de las células plasmáticas |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES10196249.6T Active ES2455440T3 (es) | 2005-01-27 | 2006-01-26 | Método de detección o seguimiento de una enfermedad maligna de las células plasmáticas |
Country Status (11)
| Country | Link |
|---|---|
| US (3) | US7897353B2 (enExample) |
| EP (2) | EP2306202B1 (enExample) |
| JP (3) | JP5431674B2 (enExample) |
| AT (1) | ATE502302T1 (enExample) |
| DE (1) | DE602006020688D1 (enExample) |
| DK (1) | DK2306202T3 (enExample) |
| ES (2) | ES2365626T7 (enExample) |
| GB (1) | GB0501741D0 (enExample) |
| PL (1) | PL2306202T3 (enExample) |
| PT (1) | PT2306202E (enExample) |
| WO (1) | WO2006079816A1 (enExample) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0608444D0 (en) | 2006-04-27 | 2006-06-07 | Binding Site The Ltd | Dialysis |
| GB0801609D0 (en) * | 2008-01-29 | 2008-03-05 | Binding Site The Ltd | Hevylite diagnostic stain |
| SG174992A1 (en) | 2009-04-01 | 2011-11-28 | Genentech Inc | Anti-fcrh5 antibodies and immunoconjugates and methods of use |
| GB0914535D0 (en) * | 2009-08-19 | 2009-09-30 | Binding Site Group The Ltd | Prognosis assay |
| GB201001946D0 (en) * | 2010-02-05 | 2010-03-24 | Binding Site Group The Ltd | Cancer prognostic assay |
| GB201001950D0 (en) * | 2010-02-05 | 2010-03-24 | Binding Site Group The Ltd | Infection prognostic assay |
| GB201012049D0 (en) | 2010-07-19 | 2010-09-01 | Binding Site Group The Ltd | Competition assay |
| GB201203938D0 (en) | 2012-03-06 | 2012-04-18 | Binding Site Group The Ltd | Assay system |
| US9550004B2 (en) | 2013-09-06 | 2017-01-24 | Sensor Electronic Technology, Inc. | Ultraviolet diffusive illumination |
| US10267806B2 (en) | 2014-04-04 | 2019-04-23 | Mayo Foundation For Medical Education And Research | Isotyping immunoglobulins using accurate molecular mass |
| GB201511364D0 (en) * | 2015-06-29 | 2015-08-12 | Binding Site Group The Ltd | Method of detecting or monitoring an IgG4-related disease |
| GB2541027A (en) * | 2015-08-07 | 2017-02-08 | The Binding Site Group Ltd | Treatment |
| US12153052B2 (en) | 2017-09-13 | 2024-11-26 | Mayo Foundation For Medical Education And Research | Identification and monitoring of immunoglobulin J chains |
| US11946937B2 (en) | 2017-09-13 | 2024-04-02 | Mayo Foundation For Medical Education And Research | Identification and monitoring of apoptosis inhibitor of macrophage |
| WO2021202992A2 (en) * | 2020-04-03 | 2021-10-07 | Lawrence Loomis | Rapid point of care assay for the detection of the asymptomatic carrier state of covid-19 |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3907502A (en) | 1973-12-11 | 1975-09-23 | Miless L Brink | Method for identifying Bence Jones proteins |
| EP0044219A1 (en) | 1980-07-16 | 1982-01-20 | Unilever Plc | Methods of immuno analysis using monoclonal antibodies |
| JPS63139199A (ja) * | 1986-12-01 | 1988-06-10 | Wakunaga Pharmaceut Co Ltd | 抗ヒトＩｇＥモノクロ−ナル抗体及びその用途 |
| ES2150428T3 (es) | 1987-04-27 | 2000-12-01 | Unilever Nv | Ensayos de union especifica. |
| US4983530A (en) * | 1988-01-29 | 1991-01-08 | E. I. Du Pont De Nemours And Company | Sandwich immunoassay for determination of total monoclonal IGG |
| US5185066A (en) * | 1988-08-11 | 1993-02-09 | Helena Laboratories Corporation | Immunofixation electrophoresis control system |
| JPH03199966A (ja) * | 1989-12-27 | 1991-08-30 | Kazutomo Wakasugi | 遊離型ｌ鎖の測定方法 |
| JPH04262792A (ja) * | 1990-01-12 | 1992-09-18 | Takeda Chem Ind Ltd | 蛋白質の精製法 |
| US5228960A (en) * | 1992-07-17 | 1993-07-20 | Beckman Instruments, Inc. | Analysis of samples by capillary electrophoretic immunosubtraction |
| US5552277A (en) * | 1994-07-19 | 1996-09-03 | The Johns Hopkins University School Of Medicine | Genetic diagnosis of prostate cancer |
| EP0862584B1 (en) | 1995-11-03 | 2004-12-22 | The Binding Site Limited | Production of antibodies |
| GB9718911D0 (en) * | 1997-09-05 | 1997-11-12 | Orion Yhtymae Oy | Monoclonal antibodies |
| ATE301131T1 (de) * | 1998-11-19 | 2005-08-15 | Elan Corp Plc | Gegen gastrointestinale transport rezeptoren gerichtete retro-invertierte peptide und deren verwendung |
| US20040163137A1 (en) * | 2001-02-20 | 2004-08-19 | Caroline Barry | PG-3 and biallelic markers thereof |
| US20020182748A1 (en) | 2001-03-30 | 2002-12-05 | Reardon Paul C. | Method and device for testing for Bence-Jones Protein |
| CA2468950A1 (en) * | 2001-11-27 | 2003-06-05 | Mochida Pharmaceutical Co., Ltd. | Anti-il13 receptor .alpha.1 neutralizing antibody |
| US20040018576A1 (en) * | 2002-07-24 | 2004-01-29 | Dematteo Todd M. | Bence Jones protein testing cassette |
| AU2004210975B2 (en) * | 2003-02-10 | 2008-04-10 | Agensys, Inc. | Nucleic acid and corresponding protein named 158P1D7 useful in the treatment and detection of bladder and other cancers |
| WO2004073656A2 (en) * | 2003-02-20 | 2004-09-02 | Seattle Genetics, Inc. | Anti-cd70 antibody-drug conjugates and their use for the treatment of cancer and immune disorders |
| JP4473257B2 (ja) * | 2003-04-02 | 2010-06-02 | エフ．ホフマン−ラ ロシュ アーゲー | インスリン様成長因子ｉ受容体に対する抗体及びその使用 |
| JP4286256B2 (ja) * | 2003-11-19 | 2009-06-24 | ヤマサ醤油株式会社 | ベンスジョーンズ蛋白質の検定法 |
| JP4438455B2 (ja) * | 2004-03-04 | 2010-03-24 | ヤマサ醤油株式会社 | 遊離ヒトイムノグロブリン軽鎖の測定法及びキット |
| WO2005116651A2 (en) * | 2004-05-24 | 2005-12-08 | Diasys Corporation | Method and device for testing for bence-jones protein |
-
2005
- 2005-01-27 GB GBGB0501741.3A patent/GB0501741D0/en not_active Ceased
-
2006
- 2006-01-26 ES ES06703629.3T patent/ES2365626T7/es active Active
- 2006-01-26 US US11/883,003 patent/US7897353B2/en active Active
- 2006-01-26 AT AT06703629T patent/ATE502302T1/de not_active IP Right Cessation
- 2006-01-26 EP EP10196249.6A patent/EP2306202B1/en active Active
- 2006-01-26 EP EP06703629.3A patent/EP1842071B3/en active Active
- 2006-01-26 WO PCT/GB2006/000267 patent/WO2006079816A1/en not_active Ceased
- 2006-01-26 PL PL10196249T patent/PL2306202T3/pl unknown
- 2006-01-26 DK DK10196249.6T patent/DK2306202T3/da active
- 2006-01-26 PT PT101962496T patent/PT2306202E/pt unknown
- 2006-01-26 DE DE602006020688T patent/DE602006020688D1/de active Active
- 2006-01-26 JP JP2007552716A patent/JP5431674B2/ja not_active Expired - Fee Related
- 2006-01-26 ES ES10196249.6T patent/ES2455440T3/es active Active
-
2011
- 2011-01-21 US US13/011,135 patent/US8415110B2/en not_active Expired - Fee Related
- 2011-01-21 US US13/011,146 patent/US8592561B2/en active Active
-
2013
- 2013-03-06 JP JP2013044306A patent/JP6007134B2/ja not_active Expired - Fee Related
- 2013-10-25 JP JP2013221946A patent/JP5715671B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| JP5715671B2 (ja) | 2015-05-13 |
| JP2008528995A (ja) | 2008-07-31 |
| EP2306202B1 (en) | 2013-12-18 |
| PT2306202E (pt) | 2014-02-27 |
| WO2006079816A1 (en) | 2006-08-03 |
| DE602006020688D1 (de) | 2011-04-28 |
| US20110177535A1 (en) | 2011-07-21 |
| US20110177977A1 (en) | 2011-07-21 |
| DK2306202T3 (da) | 2014-02-10 |
| EP2306202A1 (en) | 2011-04-06 |
| US8415110B2 (en) | 2013-04-09 |
| US7897353B2 (en) | 2011-03-01 |
| JP6007134B2 (ja) | 2016-10-12 |
| ES2455440T3 (es) | 2014-04-15 |
| GB0501741D0 (en) | 2005-03-02 |
| EP1842071B3 (en) | 2014-02-26 |
| JP2013147499A (ja) | 2013-08-01 |
| PL2306202T3 (pl) | 2014-05-30 |
| EP1842071B1 (en) | 2011-03-16 |
| JP2014025950A (ja) | 2014-02-06 |
| ES2365626T3 (es) | 2011-10-07 |
| EP1842071A1 (en) | 2007-10-10 |
| US20080166742A1 (en) | 2008-07-10 |
| ATE502302T1 (de) | 2011-04-15 |
| JP5431674B2 (ja) | 2014-03-05 |
| US8592561B2 (en) | 2013-11-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6007134B2 (ja) | 免疫グロブリン重鎖−軽鎖対に特異的である単離抗体又はその断片 | |
| US20160341721A1 (en) | Anti-human igm monoclonal antibody and immunoassay using the same | |
| CA2755486A1 (en) | Detection of fibrin and fibrinogen degradation products and associated methods of production and use for the detection and monitoring of cancer | |
| US20110312922A1 (en) | EDTA Resistant S100A12 Complexes (ERAC) | |
| US20150285804A1 (en) | Diagnostic method for colorectal cancer | |
| US12474351B2 (en) | Mass spectrometry calibrator | |
| US11242408B2 (en) | Monoclonal antibody specific for gamma-glutamyl-l-epsilon-lysine for the monitoring of apoptosis | |
| JPWO2008099608A1 (ja) | 炎症性腸疾患の診断方法 | |
| US20100248269A1 (en) | Detection of fibrin and fibrinogen degradation products and associated methods of production and use for the detection and monitoring of cancer | |
| CN109313193B (zh) | 消化道癌的判定方法 | |
| CN107076760A (zh) | 用于评估先兆子痫的生物标志物 | |
| JP7671956B2 (ja) | 抗原の測定方法及び固相化抗体の製造方法 | |
| JP2013519082A (ja) | がん予後診断アッセイ | |
| Pande | Immunochemistry Techniques | |
| CN118786347A (zh) | 丝氨酸蛋白酶的检测用或测定用试剂 | |
| Leach et al. | False reactivity in GTI Pak Plus® ELISA kits due to the presence of anti-mouse antibody in patients' samples | |
| WO2022202876A1 (ja) | Ｉ型コラーゲンｃ末端テロペプチドの免疫学的分析方法 | |
| Chourb | Enhanced immuno-detection of breast cancer biomarkers: Shed extracellular domain of Her-2/neu and CA 15-3 |